Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Dementia01:30

Dementia

416
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
416
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

651
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
651

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Landscape of copy number variants in Spanish people with dementia.

NPJ genomic medicine·2026
Same author

Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform.

Alzheimer's research & therapy·2026
Same author

A familiar case with an unfamiliar turn.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Amyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies.

Alzheimer's & dementia (Amsterdam, Netherlands)·2025
Same author

Development of amyloid-negative neuropsychological norms using GAMLSS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2025
Same author

Early microglial and astrocyte reactivity in preclinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Causal intervention validation of gene regulatory signals in scGPT.

Journal of biomedical informatics·2026
Same journal

CoAff-DTI: Fine-grained drug-target interaction prediction using pre-trained language models and affinity-guided mechanisms.

Journal of biomedical informatics·2026
Same journal

Evaluation of temporal preservation in synthetic longitudinal patient data.

Journal of biomedical informatics·2026
Same journal

ARKE: An ontology-driven framework for automated mapping of local radiology procedure terms to the LOINC-RadLex playbook using large language model.

Journal of biomedical informatics·2026
Same journal

A validation-driven training controller for cross-lingual biomedical NER via reinforcement learning-based adaptive loss weighting.

Journal of biomedical informatics·2026
Same journal

ASP-HR: An Adaptive Spatial Perception and Hierarchical Reasoning mechanism for document-level biomedical relation extraction.

Journal of biomedical informatics·2026
See all related articles

Related Experiment Video

Updated: Dec 13, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K

Alzheimer's Disease stage identification using deep learning models.

Santos Bringas1, Sergio Salomón2, Rafael Duque3

  • 1Fundación Centro Tecnológico de Componentes CTC, 39011 Santander, Spain.

Journal of Biomedical Informatics
|July 26, 2020
PubMed
Summary
This summary is machine-generated.

This study uses smartphone mobility data and deep learning to accurately identify Alzheimer's Disease (AD) stages. This advancement aids in disease monitoring and personalized treatment strategies for AD patients.

Keywords:
AccelerometerAlzheimer’s diseaseConvolutional neural networkDeep learning

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

645
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.8K

Related Experiment Videos

Last Updated: Dec 13, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

645
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.8K

Area of Science:

  • Neurology
  • Biomedical Engineering
  • Data Science

Background:

  • Alzheimer's Disease (AD) diagnosis and staging are crucial for effective patient management.
  • Current methods for monitoring AD progression can be invasive or resource-intensive.
  • Objective staging of AD using objective patient data is an unmet need.

Purpose of the Study:

  • To develop a deep learning model for identifying Alzheimer's Disease stages using mobility data.
  • To leverage smartphone-collected accelerometer data for non-invasive AD patient monitoring.
  • To improve the accuracy of AD stage identification compared to traditional methods.

Main Methods:

  • Collected accelerometer data from 35 Alzheimer's Disease patients over one week using smartphones.
  • Processed time-series mobility data, labeling it with disease stages (early, middle, late).
  • Utilized a Convolutional Neural Network (CNN) model to recognize patterns indicative of each AD stage.

Main Results:

  • The CNN-based approach achieved 90.91% accuracy in identifying AD stages.
  • An F1-score of 0.897 was obtained, demonstrating robust performance.
  • Significantly outperformed traditional feature-based classifiers in accuracy.

Conclusions:

  • Mobility data is a valuable resource for monitoring Alzheimer's Disease progression.
  • The developed CNN model enhances the accuracy of AD stage identification.
  • This approach offers a promising non-invasive tool for AD patient management and treatment optimization.